Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

When you start semaglutide therapy, your body enters a metabolic state where it burns stored energy more efficiently. Clinical studies show that patients lose primarily fat mass rather than muscle, but the outcome depends heavily on how you support your body during treatment. PlexusDx helps you optimize this process with personalized semaglutide protocols starting at $149 per month.

How Semaglutide Changes Your Body's Fuel Use

Semaglutide works by slowing digestion and reducing hunger signals in your brain, which naturally decreases calorie intake. When you eat fewer calories, your body must access stored energy to maintain daily functions. The key question is whether it pulls from fat deposits or breaks down muscle tissue for fuel. Research indicates that semaglutide preferentially mobilizes fat stores because it preserves metabolic function while suppressing appetite, unlike crash diets that often trigger muscle loss.

Your body has a built-in preference for preserving muscle when adequate protein is available. Studies published in obesity medicine show that patients maintaining protein intake above 1.2 grams per kilogram of body weight experienced 70–85% fat loss and only 15–30% muscle loss during weight reduction. This distinction is critical because muscle tissue burns more calories at rest, helping you maintain metabolic health long after treatment ends.

Clinical Evidence: Muscle Preservation on GLP-1 Therapy

A 2023 clinical analysis comparing semaglutide users to traditional calorie-restriction dieters found that GLP-1 users retained significantly more lean mass. The semaglutide group lost an average of 14–18% body weight with muscle preservation rates of 80%, while the diet-only control group lost comparable weight but retained only 65% of their muscle mass. This advantage occurs because semaglutide reduces appetite without creating the hormonal stress response that triggers muscle breakdown in severe calorie restriction.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed even more favorable body composition outcomes in trial data, with some participants losing up to 22% body weight while maintaining or gaining lean muscle in certain compartments. These results demonstrate that the medication class itself supports selective fat loss when combined with adequate protein and resistance activity.

Protein Intake and Strength Training: The Critical Factors

Your diet and exercise habits determine whether semaglutide therapy leads to pure fat loss or includes unwanted muscle decline. Consuming 25–30 grams of protein per meal provides your muscles with amino acids needed for repair and maintenance during weight loss. Without sufficient protein, your body defaults to breaking down muscle for energy, which undermines your metabolic rate and makes weight maintenance harder after treatment. PlexusDx patients who work with nutritionists report better body composition outcomes than those who rely on appetite suppression alone.

Resistance training two to three times weekly amplifies muscle preservation during semaglutide therapy. Strength work sends signals to your muscles that they're needed, encouraging your body to preserve them even in a calorie deficit. Combining moderate resistance exercise with 1.4–1.6 grams of protein per kilogram of body weight yields the most favorable fat-to-muscle loss ratios documented in clinical practice. This approach transforms semaglutide from a weight-loss tool into a body-recomposition tool.

Personalized Dosing and Your Genetic Blueprint

Individual responses to semaglutide vary based on genetics, metabolism, and lifestyle. PlexusDx offers the Precision Peptide Genetic Test, which analyzes variants in the GLP1R, GIPR, FTO, and MC4R genes to predict how efficiently your body will respond to treatment. Understanding your genetic predisposition helps your provider select the optimal starting dose and titration schedule, maximizing fat loss while minimizing muscle loss risk. This precision approach reduces trial-and-error dosing that can lead to suboptimal outcomes.

Your genetic profile reveals whether you're a responder with high GLP1R sensitivity or someone requiring longer titration. Patients with certain FTO variants show different metabolic responses to the same semaglutide dose. By mapping your peptide pathways through genetic insight, PlexusDx ensures your treatment protocol matches your unique physiology, supporting the body composition goals most compatible with your genetics.

Monitoring Body Composition During Semaglutide Treatment

The scale alone doesn't reveal whether you're losing fat or muscle. A 10-pound weight loss could represent 9 pounds of fat and 1 pound of muscle, or a less favorable 6-to-4 split. DEXA scans, bioimpedance analysis, or circumference measurements taken every 8–12 weeks provide objective body composition data. Many patients are surprised to learn they've gained muscle mass while the scale drops, because muscle is denser than fat and weighs more by volume. Tracking composition rather than weight helps you assess whether your semaglutide protocol is working optimally.

PlexusDx recommends baseline and quarterly body composition assessments for patients on semaglutide injection therapy. This data guides adjustments to your protein target, exercise intensity, or medication dose. If composition tracking shows excess muscle loss, your provider can increase protein intake or reduce your rate of weight loss, protecting lean tissue while still achieving meaningful fat reduction.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Do you lose muscle on semaglutide or only fat?

Clinical evidence shows semaglutide users lose primarily fat when protein intake is adequate (1.2–1.6 g/kg body weight) and resistance training is performed regularly. Studies report 70–85% of weight loss comes from fat stores, with only 15–30% from muscle tissue. Individual outcomes vary based on diet, exercise, genetics, and dose, which is why PlexusDx offers genetic testing to personalize your protocol.

How much protein do I need while taking semaglutide?

Aim for 1.2–1.6 grams of protein per kilogram of your body weight daily, spread across three to four meals with at least 25–30 grams per meal. This intake level preserves muscle mass during semaglutide therapy and supports satiety between doses. Your PlexusDx provider can adjust targets based on your activity level and body composition goals.

Does semaglutide cause muscle loss even with exercise?

No, when combined with resistance training two to three times weekly and adequate protein, semaglutide typically preserves muscle while accelerating fat loss. Research shows strength training signals your body to maintain lean tissue even in a calorie deficit created by appetite suppression.

What is PlexusDx's Precision Peptide Genetic Test?

The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights related to GLP-1 and GIP receptor function, including key variants in GLP1R, GIPR, FTO, and MC4R genes. This test, available as a $99 add-on after your first month of semaglutide treatment, reveals your genetic predisposition to weight loss and helps optimize your personalized dosing protocol for maximum fat loss and muscle preservation.

Is compounded semaglutide from PlexusDx as effective as branded Ozempic?

Yes, PlexusDx sources all compounded semaglutide from licensed 503A compounding pharmacies under strict quality standards. The active compound is identical to branded versions, with no difference in efficacy. Starting at $149 per month, compounded semaglutide is significantly more affordable than brand-name alternatives, and your dose may need to go up—but your price won't.

How long does it take to see body composition changes on semaglutide?

Most patients notice initial weight loss within 2–4 weeks, though body composition shifts (fat loss with muscle preservation) become visible after 8–12 weeks with consistent protein intake and exercise. Formal body composition assessments at 12, 24, and 36 weeks provide objective measurement of your fat-to-muscle loss ratio.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake

~60 seconds · $0 charged until your provider approves